Table 2

Univariate and multivariate logistic regression analysis for predicting pregnancy failure after fertility-sparing hormonal treatment for early endometrial cancer

Univariate analysisMultivariate analysis
OR (95% CI)P valuesOR (95% CI)P values
Age1.05 (0.9 to 1.2)0.471.05 (0.8 to 1.3)0.69
BMI
 Normal to over weight1
 Obesity1.12 (0.3 to 3.5)0.85
Grade
 11
 24.75 (0.9 to 25.0)0.066.2 (1.0 to 38.9)<0.05
PCO in ultrasonography0.8 (0.2 to 2.7)0.72
Operation history0.98 (0.3 to 3.0)0.97
Medical history00.99
Initial CA 1250.97 (0.9 to 1.0)0.3
Superficial myometrium invasion0.76 (0.1 to 4.2)0.75
Endometrial mass size
 <1 cm1
 >1 cm0.8 (0.09 to 6.0)0.77
Treatment time
 ≤9 months1
 >9 months0.83 (0.26 to 2.6)0.75
Remission months
 ≤6 months1
 >6 months1.8 (0.5 to 5.6)0.31
MPA dose
 500 mg, once daily1
 1000 mg, once daily1.5 (0.4 to 5.3)0.47
Number of D&Cs
 ≤3
 >31.6 (0.5 to 5.0)0.42
Initial endometrium thickness0.9 (0.8 to 1.0)0.31
 ≤10 mm
 >10 mm0.31 (0.07 to 1.2)0.0970.23 (0.4 to 1.0)0.06
End of treatment endometrial thickness
 <4 mm
 ≥4 mm0.71 (0.2 to 2.2)0.57
  • BMI, kg/m2 (Korean Society for the Study of Obesity: normal BMI 18.5–23; overweight 23–25; obesity >25).

  • BMI, body mass index; CA, cancer antigen; D&C, dilatation and curettage; MPA, medroxyprogesterone acetate; PCO, polycystic ovary.